Technical Data Sheet

InVivoMAb anti-human CEACAM5

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at https://bioxcell.com/terms-and-conditions.

Lot Specific Information

Lot Number:	**Lot Specific***
Volume:	**Lot Specific***
Concentration:	**Lot Specific* (generally 4 to 11 mg/ml) ***
Total Protein:	**Lot Specific***

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	**BE0401**
Clone:	**4H11-8**
Isotype:	Mouse IgG1, κ
Recommended Isotype Control(s):	InVivoMAb mouse IgG1 isotype control, unknown specificity
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	≤1EU/mg (≤0.001EU/µg) Determined by LAL gel clotting assay
Purity:	≥95% Determined by SDS-PAGE
Sterility:	0.2 µm filtered
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein G
RRID:	
Molecular Weight:	150 kDa

Description

The 4H11-8 monoclonal antibody reacts with human CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5). CEACAM5 is a cell surface protein that was discovered as a founding member of the carcinoembryonic antigen (CEA) family of proteins, and it is often called CEA or CD66e. CEACAM5 is expressed in the digestive system during the fetal or early embryonic stages and in neoplastic tissues. CEACAM5 acts as a cell adhesion molecule, and it mediates inter-cellular contact through both homophilic (CEACAM5 to CEACAM5) and heterophilic (CEACAM5 to CEACAM1 or CEACAM6) interactions. CEACAM5 inhibits anoikis, a type of apoptosis that is induced upon cell detachment from the ECM, and through this mechanism, CEACAM5 facilitates tumorigenesis and metastasis. CEACAM5 has a very low expression in normal adult tissues, and its expression gets upregulated in a variety of human epithelial malignancies such as breast cancer, colon cancer, lung cancer, neuro-endocrine prostate cancer (NEPC), and pancreatic cancers. CEACAM5 overexpression is directly linked to the processes of differentiation, invasion, and metastasis in various tumors. In cancer immunotherapy research, CEACAM5-targeted vaccines, bispecific T cell engagers (BiTEs), CAR T cell therapies, and antibody-drug conjugates are routinely tested in various experimental models.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**
It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at https://bioxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate

dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/be0401?bxcs=9k1b3a#tab_references or scan the QR code below.

Bio X Cell, LLC
https://bioxcell.com
+1-866-787-3444
customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.
Not for resale.
Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC